Abstract:S9.3 Drug resistance in emerging pathogenic fungi, September 23, 2022, 4:45 PM - 6:15 PM Candida albicans is an opportunistic fungal pathogen. While nearly 40%-60% of humans are colonized harmlessly by C. albicans , prolonged use of antibiotics or an immune-compromised status can lead to mucosal or deadly systemic candidiasis (Kumamoto et al., 2020). There are only three classes of antifungals available to physicians to treat and prevent severe Candidiasis. These drugs, which include polyenes, echinocandins, and azoles, protect the host by killing or inhibiting growth of C. albicans , thereby exerting a strong selective pressure toward drug resistance.Antivirulence drugs, by contrast, target virulence traits of pathogens without affecting their growth, making drug resistance less likely to evolve. We seek to discover novel antivirulence compounds against C. albicans that keep it at, or return it to, its baseline commensal state even under conditions that support pathogenicity.Bacteria have evolved a large repository of metabolites that can inhibit and modulate the behavior of other organisms in their environment. Clades like the predatory myxobacteria are untapped for potential antifungal and antivirulence drug discovery (Vij et al., 2021). We here screened ≈ 2800 crude extracts from myxobacteria in an in situ C. albicans -mammalian epithelial cell infection model. Typically, when oral epithelial cells (TR146) are infected by C. albicans , the fungus proliferates, forms hyphae, and invades and damages the monolayer. In our assay, we estimate the damage to epithelial cells by released lactate dehydrogenase. We also note changes to the growth and morphology of the fungus. Based on these readouts we assign antivirulence and antifungal ranks to each extract, and confirm top-ranked hits with an independent propidium iodide-based assay for host cell damage, and a colorimetric assay of fungal metabolic activity. We found that several of the top-ranked antifungal extracts also showed effects on a multi-drug resistant strain of C. auris .Using an established pipeline, we identified several of the antifungal and antivirulent bioactive components in these extracts. After scaling the production of promising lead compounds, we will test their drugability on clinical Candida spp. strains, and identify their mode of action using large-scale Candida spp. knock-out libraries and multi-omics approaches.Our tested extracts are likely to contain new classes of non-toxic antifungals that can potentially treat infections by multi-drug resistant fungi. We identified and confirmed several myxobacteria extracts that protected mammalian epithelial cells without severely affecting the fungus' growth, which are, therefore, considered antivirulent.Sources: Kumamoto, C. A., Gresnigt, M.S., Hube, B., 2020. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr. Opin. Microbiol. 56, 7–15. https://doi.org/10.1016/j.mib.2020.05.006 Vij, R., Hube, B., Brunke, S., 2021. Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria. Comput. Struct. Biotechnol. J. 19, 1244–1252. https://doi.org/10.1016/j.csbj.2021.02.003

A marine microbiome antifungal targets urgent-threat drug-resistant fungi

Bioactive Metabolites From The Mariana Trench Sediment-Derived Fungus Penicillium Sp. Sy2107

Deep-Sea Fungi Could Be the New Arsenal for Bioactive Molecules.

Marine-Derived Metabolites Act as Promising Antifungal Agents

Unsaturated fatty acid perturbation combats emerging triazole antifungal resistance in the human fungal pathogen Aspergillus fumigatus

High-throughput Synergy Screening Identifies Microbial Metabolites As Combination Agents for the Treatment of Fungal Infections.

Extremophilic Fungi from Marine Environments: Underexplored Sources of Antitumor, Anti-Infective and Other Biologically Active Agents

Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in Cryptococcus neoformans

Antifungal and Antiviral Products of Marine Organisms

S9.3d Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria.

MBX-7591: a promising drug candidate against drug-resistant fungal infections

Metal Complexes as Antifungals? From a Crowd-Sourced Compound Library to the First In Vivo Experiments

Marine fungi showing multifunctional activity against human pathogenic microbes and cancer

Antibacterial Activity and AbFtsZ Binding Properties of Fungal Metabolites Isolated from Mexican Mangroves

An Overview of the Mechanisms of Marine Fungi-Derived Anti-Inflammatory and Anti-Tumor Agents and Their Novel Role in Drug Targeting

Antifungal and New Metabolites of Myrothecium Sp Z16, A Fungus Associated with White Croaker Argyrosomus Argentatus

Secondary metabolites from the deep-sea derived fungus Aspergillus terreus MCCC M28183

Antifungal Compounds from Microbial Symbionts Associated with Aquatic Animals and Cellular Targets: A Review

Antibacterial properties of natural products from marine fungi reported between 2012 and 2023: a review

Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti- Burkholderia activity

Bioactivity and Metabolome Mining of Deep-Sea Sediment-Derived Microorganisms Reveal New Hybrid PKS-NRPS Macrolactone from Aspergillus versicolor PS108-62